Shots:

• The studies will evaluate 5-day and a 10-day dosing regimen of remdesivir (IV). One study will assess remdesivir + SOC in ~400 patients in a ratio (1:1) with sev. clinical manifestations of COVID-19 while the second study will assess remdesivir vs SOC as monothx. in ~600 patients in a ratio (1:1:1) with mod. clinical manifestations of the disease
• The initiation follows the US FDA rapid review & acceptance of Gilead’s IND filing for remdesivir to treat COVID-19. The studies will expand the ongoing research of the therapy which include clinical trials in China’s Hubei province and the US
• Remdesivir is an investigational nucleotide analog with broad-spectrum antiviral activity both in vitro/ vivo in animal models against viral pathogens including Ebola- Marburg- MERS and SARS

Click here ­to­ read full press release/ article 

Ref: Gilead  | Image:Gilead